🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Robert Belknap

University of Colorado Hospital

ORCID: 0000-0002-7382-8592

Also affiliated with Hospital Authority, Denver Health Medical Center, Denver Public Health, Public Health Institute, University of Colorado Anschutz Medical Campus, University of Colorado Denver

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study”.

Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study

The Lancet Infectious Diseases(2021)10.1016/s1473-3099(21)00145-6

N/A

1.1DataRank · unranked

35 citations

Pei-Jean Feng, Masahiro Narita, Jason E. Stout, Michael Chen, Lisa Pascopella +23 more

Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection

Clinical Infectious Diseases(2023)10.1093/cid/ciad083

N/A

0.655DataRank · unranked

15 citations

Robert Belknap, David P. Holland, Ruth N. Moro, Michael P. Chen, Alicia Wright +6 more

Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda

Implementation Science(2020)10.1186/s13012-020-01025-8

N/A

0.558DataRank · unranked

23 citations

Allan Musinguzi, Juliet Nabunje, Fred Welishe, Jackie Ssemata, Bishop Opira +16 more

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial

PLoS Medicine(2024)10.1371/journal.pmed.1004356

N/A

0.478DataRank · unranked

11 citations

Jillian L. Kadota, Allan Musinguzi, Fred Welishe, Anne Nakitende, Lydia Akello +20 more

Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial

PLOS Global Public Health(2024)10.1371/journal.pgph.0003347

N/A

0.241DataRank · unranked

4 citations

Joan Ritar Kasidi, Jillian L. Kadota, Fred Welishe, Anne Nakitende, Lydia Akello +20 more

Transmission of Mycobacterium tuberculosis to Healthcare Personnel Resulting From Contaminated Bone Graft Material, United States, June 2021–August 2022

Clinical Infectious Diseases(2023)10.1093/cid/ciad029

N/A

0DataRank · unranked

11 citations

Molly Deutsch-Feldman, Tamasin Adams, Michelle Law, Biak Chinpar, Erika Pitcher +90 more

Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine

Contemporary Clinical Trials(2023)10.1016/j.cct.2023.107173

N/A

0DataRank · unranked

5 citations

Claire Sadowski, Andrew Vernon, Bert Arevalo, Karlyn D. Beer, Andrey V. Borisov +10 more

Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States

Annals of the American Thoracic Society(2023)10.1513/annalsats.202212-1005oc

N/A

0DataRank · unranked

3 citations

Kathryn Winglee, Christine Ho, April C. Pettit, Amina Ahmed, Dolly Katz +3 more

Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV)

Clinical Infectious Diseases(2020)10.1093/cid/ciaa1135

N/A

0DataRank · unranked

13 citations

Jason E. Stout, Robert Belknap, Constance A. Benson, Marie Nancy Séraphin, Michael Lauzardo +19 more

Reasons for acceptance or nonparticipation in iAdhere: a trial of latent TB infection treatment

The International Journal of Tuberculosis and Lung Disease(2024)10.5588/ijtld.23.0599

N/A

0DataRank · unranked

1 citations

Nigel Scott, Robert Belknap, Stefan Goldberg, Melissa Engle, Andrey Borisov +2 more

Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study

Antimicrobial Agents and Chemotherapy(2021)10.1128/aac.01705-21

N/A

0DataRank · unranked

6 citations

Jacqueline P. Ernest, Nan Zhang, Nicole C. Ammerman, Eric L. Nuermberger, Robert Belknap +4 more

Variability of interferon-γ release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States

Clinical Microbiology and Infection(2022)10.1016/j.cmi.2022.02.020

N/A

0DataRank · unranked

4 citations

Andrew Hill, Robert Belknap, Jason E. Stout, Tracy Ayers, Kathryn Winglee

Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease

Clinical Infectious Diseases(2023)10.1093/cid/ciad312

N/A

0DataRank · unranked

46 citations

Marcos C. Schechter, David Ashkin, Charles A. Peloquin, J. Peter Cegielski, Barbara B Andrino +95 more

Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(23)00096-6

N/A

0DataRank · unranked

39 citations

Robert Belknap, Andrea Benedetti, Andrey Borisov, Jonathon R. Campbell, Richard E. Chaisson +10 more